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Photodynamic targeting of human retinoblastoma cells
using covalent low-density lipoprotein conjugates
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Summary Combination of photosensitizers with carrier molecules has been shown to enhance the efficiency ofphotodynamic therapy (PDT).
Owing to an increased expression of their receptors on some malignant and proliferating cells, low-density lipoproteins (LDLs) are potential
endogenous carriers. A photosensitizer, chlorin e6 (Ce6), was covalently bound to LDL via carbodiimide activation. The Ce6-LDL conjugate
was evaluated on a fibroblast cell line with defined LDL receptor expression and a retinoblastoma cell line (Y79). Uptake of free Ce6 and Ce6
either covalently bound to or complexed with LDL was measured by spectrofluorimetry. Phototoxicity after irradiation at 660 nm was
determined by a mitochondrial activity assay (MTT). Covalent binding to LDL significantly increased the uptake of Ce6 for both cell lines by a
factor of 4-5. A Ce6: LDL binding ratio of 50:1 was optimal. A receptor-mediated uptake was demonstrated by saturability and competitive
inhibition by free LDL. Binding also occurred at 20C and was attributed to non-specific associations. Irradiation with 10 J cm-2 of 660 nm light
after treatment of cells with Ce6-LDL conjugate reduced the MTT activity by 80%, while free or mixed Ce6 induced a maximum of 10%
reduction in the MTT activity following identical treatment conditions. These data suggest that targeting of LDL receptor-bearing cells using
covalently bound carriers, such as LDL, might increase the efficiency and selectivity of PDT. Intraocular tumours such as retinoblastomas
could be appropriate targets for such an approach owing to the ease of access of light sources and the need for non-invasive approaches in
sensitive ocular sites.
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Photodynamic therapy (PDT) is a non-invasive modality, which
may be used to treat tumours in situations not easily amenable to
surgery (Dougherty, 1989; van Hillegersberg et al, 1994; Hasan and
Parrish, 1996). It involves administration of a light-activatable
chemical photosensitizer (PS), accumulation of the PS within
neoplastic tissue somewhat preferentially, and spatially confined
light exposure of the lesion, including a limited volume
surrounding it (Henderson and Dougherty, 1992). Generation of
cytotoxic species, such as singlet oxygen, leads to irreversible
tumour destruction (Weishaupt et al, 1976). Although PDT
provides many advantages for the treatment of small tumours
within transparent media, such as within the eye, early clinical trials
were disappointing (Bruce, 1987; Murphree et al, 1987; Tse et al,
1989). Tumour regression was incomplete, while damage to extra-
tumoral structures was significant. This could be attributed to the
nature of the PS, haematoporphyrin derivative (HPD) or Photofrin
(PF) used in these studies. HPD and its somewhat purified form PF
are poorly defined mixtures of porphyrins (Dougherty, 1987) with
significant non-specific tissue localization, including in the skin.
This leads to phototoxicity to normal structures and, in the case of
skin, to prolonged cutaneous phototoxicity. Therefore, there has
been increased activity in the search for better-localizing PS.
Although new PS with improved localization properties are
being developed (Gomer, 1991), most sensitizing drugs per se do
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not provide any pronounced preferential or selective tumour
affinity (Henderson and Dougherty, 1992). Better methods of
localization in which sensitizers are combined with carriers that
recognize the target tissue may therefore be useful in certain
instances in order to increase the selective accumulation of the
PS within the tumour (Jori, 1990; Hasan, 1992; Hamblin and
Newman, 1994). Such delivery systems include monoclonal anti-
bodies (MAbs) (Mew et al, 1983; Oseroff et al, 1986; Jiang et al,
1991), liposomes (Jori, 1990; Jori and Reddi, 1990), low-density
lipoproteins (LDLs) (Mosley et al, 1981; Jori et al, 1984; Schmidt-
Erfurth et al, 1994) and microspheres (Bachor et al, 199la). MAbs
exhibit the highest selectivity, but their uptake by the target tissue
is limited by vascular barrier problems and rapid clearance by the
reticuloendothelial system. Repetitive use of non-human-derived
antibody conjugates invariably elicits an immune response,
leading to the formation ofanti-antibodies.
Owing to the inherent dual selectivity ofPDT through preferen-
tial PS localization and spatial control of photoactivation, the
requirement for the specificity of carrier systems used in PDT
could, in principle, be less stringent than for modalities, such as
chemo- and radiotherapy. For this study, we selected covalent
conjugates ofan endogenous delivery system, human LDL, which
is known to possess high-affinity receptors on certain neoplastic
andproliferating cells at significantly increased numbers (Gal et al,
1981; Vitols et al, 1985). A number of investigators have demon-
strated that photosensitizers mixed non-covalently with LDL
before administration showed enhanced photodynamic activity
compared with the administration of the photosensitizer alone
(Mosley et al, 1981; Jori, 1984, 1990; Jori et al, 1990; Maziere et
al, 1990; Schmidt-Erfurth et al, 1994). However, covalently linked
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LDL-PS conjugates have rarely been used in PDT. There has been
one report of covalent conjugates between LDL and the PS
haematoporphyrin (Hamblin and Newman, 1994). These authors
found that LDL-HP showed some apoB/E receptor-mediated
uptake in HT29 colorectal tumour cells and in fibroblasts, but a
dramatic increase in uptake via the apoB/E receptor-mediated
phagocytosis pathway, which is characteristic ofmacrophage-type
cells (Suits et al, 1989). A comparison with non-covalent mixture
of HP-LDL was not made.
The use of covalent conjugates might be advantageous as it
obviates the exchange of the PS with non-tumour-targeting blood
components. The goal of the experiments described below was to
determine whether the covalent coupling of sensitizer to the
lipoprotein carrier could enhance cellular uptake and whether
increased uptake would translate into enhanced phototoxicity. A
critical issue in any such investigation is the synthesis ofthe cova-
lent conjugate without significant interference with the receptor
recognition site. In this study, we report conditions to bind LDL
molecules covalently to a second-generation photosensitizer,
chlorin e6 (Ce6). Recognition by the LDL-receptor and uptake
were tested in proliferating human fibroblasts with characteristi-
cally high receptor activity (Anderson et al, 1978). Subsequently,
Ce6-LDL conjugates were used for the targeted photosensitization
of human retinoblastoma cells in vitro. Uptake mechanisms were
studied with respect to their receptor dependence and whether the
compound was actively intemalized into the target cells.
MATERIALS AND METHODS
Cells
Human skin fibroblasts (GM 03348 C) were purchased from the
Human Genetic Mutant Cell Depository (Camden, NJ, USA).
Cells were grown in modified Eagle medium supplemented with
5% inactivated (Gibco, Grand Island, NY, USA) fetal bovine
serum (FBS) in a 37°C, 95% air, 5% carbon dioxide atmosphere.
For experiments, cells from stock cultures from passage 10-12 in
exponential growth phase were harvested, counted and plated into
35-mm-diameter plastic dishes in appropriate numbers. Y79
human retinoblastoma cells (American Type Culture, Rockville,
MD, USA) were maintained as a suspension in a humidified
atmosphere of 5% carbon dioxide, 95% air at 37°C in Dulbecco's
modified Eagle medium supplemented with 10% horse serum
and 2.5% FBS. For experimental use, cells were plated on
35-mm tissue-culture dishes previously coated with poly-D-lysine
(0.1 mg ml,-' Sigma, St Louis, MO, USA).
Preparation of Ce6-LDL conjugates
Human LDL was prepared from plasma by agarose-column chro-
matography essentially as describedby Rudel et al (1974). All LDL
preparations contained 1 mm EDTA. LDL in solution was quanti-
fied by measuring the protein content by a Lowry test (Larson et al,
1986). Ce6 (Porphyrin Products, Logan, UT, USA) was dissolved in
0.1 M aqueous sodium hydroxide, diluted in Dulbecco's phosphate-
buffered saline (DPBS) and neutralized with 0.1 M hydrochloric
acid. For covalent coupling ofCe6 to LDL a 5-JM Ce6 solution was
activated with 0.5 mm I-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDAC) followed immediately by the drop-wise addition of
appropriate amounts ofLDL solution, according to the desired ratio
of Ce6:LDL. Preparation of Ce6-LDL complexes was performed
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Figure 1 Absorbance spectra of free Ce6 and Ce6 covalently bound to LDL
(Ce6-LDL). Binding induces a distinct red shift of 10 nm from 655 nm with
free Ce6 to 665 nm with the covalent Ce6-LDL conjugate
similarly without activation with EDAC. All compounds were incu-
bated at the same concentration for 24 h at 4°C in a rotator at low
speed. Binding was documented by spectroscopic measurement of
the absorption spectrum from 400 to 800 nm offree Ce6 and conju-
gated Ce6-LDL using a diode-array spectrophotometer (Hewlett-
Packard Model 8451 A). Covalent binding of LDL to Ce6 was
characterized by ared shift oftheabsorption peak from 655 nmwith
free Ce6 to 665 nm with the Ce6-LDL conjugate (Figure 1).
Determination of uptake of Ce6, Ce6-LDL complex and
Ce6-LDL conjugates
Subconfluent cultures ofthe human fibroblasts and retinoblastoma
cells in 35-mm dishes were incubated at 37°C or 2°C in the dark
using 0.5 gM equivalent of Ce6 free, complexed or conjugated to
LDL. Incubation times ranged from 30 min to 24 h. At intervals of
0.5, 1, 2 h or 0.5, 1, 2, 4, 8, 12 and 24 h, dishes were washed three
times with DPBS containing 10% FBS. Cells were lysed by
treating with 1 ml of0.IM sodium hydroxide in the 35-mm dishes
for 10 min. The lysate was then dispersed with a pipette and trans-
ferred to a test tube. The dish was rinsed with another 1 ml of
0.1 M sodium hydroxide and the liquid added to the lysate. The
fluorescence ofthe combined and the thoroughly mixed lysate was
analysed by spectrofluorimetry (Fluorolog 2, Spex Industries,
Edison, NJ, USA). Fluorescence emission spectra were recorded
from 600 to 800 nm with excitation at 406 nm. Known standard
solutions containing appropriate dilutions of Ce6 alone or mixed
with LDL in combination with cell lysate were used to establish a
calibration curve. The integrated fluorescence from each sample
was measured, the concentration ofCe6 was determined and corre-
lated to the number of cells in the specific subset of samples. The
data were expressed as nmol Ce6 per 106 cells. Dishes in triplicates
were used for all time points and experiments were repeated 2-3
times. Cell numbers, determined on a Coulter counter, were based
on an aliquot from each sample.
Todemonstrate receptor-mediated binding ofCe6-LDL, acompet-
itive binding experiment was performed. After incubation with
Ce6-LDL conjugates for 4 h, free LDL was added in fivefold molar
excess to one set of dishes, while the other set received an equal
volume of additional medium. These experiments were designed to
establish whether or not LDL could displace the bound conjugate.
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Figure 2 Uptake of conjugated Ce6-LDL at different binding ratios
following 0.5, 1 and 2 h of incubation with in human fibroblasts. Data for free
Ce6 are shown for comparison by the empty bars. For a given time point,
each bar represents a specific molar ratio of Ce6:LDL. It is clear that for each
time point, uptake of Ce6 LDL at a ratio of 50 Ce6 molecules per LDL carrier
is superior. Ratios indicate the molecular quantities as used in the
preparation of conjugates. Error bars represent standard errors of mean
(s.e.m.) (P<0.05)
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Figure 4 Uptake of free Ce6 and Ce6-conjugate at different temperatures for
human fibroblasts. Free Ce6 is taken up at very low rates at both
temperatures. Binding of Ce6-conjugate to surface receptors demonstrates
an increased, but stable, uptake at 20C, while 370C facilitates internalization
and recycling of receptors, as shown by the enhanced uptake
Phototoxicity assay
Subconfluent cultures ofretinoblastoma cells (typically 1.5-2 x 106
cells per dish) were treated with 4 nmol ofCe6 or Ce6 equivalent in
the Ce6-LDL conjugate complex, and incubated for 2 h in 1 ml of
complete medium. Cultures were then washed three times with
medium and fresh medium (without phenol red) was added. An
argon ion pumped-dye laser was used for all irradiations. The light
from the dye laser coupled into a 1-mm quartz fibre and focused
onto the Petri dishes via microscopic objective lens. Irradiation
using 660 nm was performed at an irradiance of50 m W cm-2 and a
fluence of 10 J cm-2 at room temperature. Control dishes contained
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Figure 3 Uptake of free Ce6 (a), Ce6-LDL conjugate (+) and Ce6 mixed with
LDL (*) by fibroblasts. Equivalent Ce6 concentrations of 0.5 gM were added
for incubation in subconfluent cell cultures. Cells were subsequently lysed
with 0.1 M sodium hydroxide and the photosensitizer extracted and analysed
as described. Error bars represent s.e.m.(P<0.05)
cells incubated with medium only. To evaluate light-independent
toxicity of the compounds, additional dishes containing cells
treated with either Ce6' LDL, Ce6-LDL complex or Ce6-LDL
conjugate were analysed in the dark. Phototoxicity/toxicity was
documented by the MTT assay essentially as described by Sargent
and Taylor (1989). Following appropriate treatments, cells were
grown in complete medium for 72 h after irradiation. Medium was
removed and 1 ml of 1 mg ml- tetrazolium salt MTT (Sigma) in
Hanks' balanced salt solution (HBSS) was added. The plates were
reincubated for an additional 4 h. The formazan crystals were
dissolved in DMSO and the concentration measured colorimetri-
cally. Control dishes were assumed to represent 100% activity for a
given cell line and the toxicity/phototoxicity data were evaluated
relative to these controls.
RESULTS
The initial experiments determining optimal binding ratios of
Ce6:LDL (Figure 2), the effect of covalent binding (Figure 3) and
the documentation ofreceptor-mediated pathways (Figure 4) were
carried out on the GM03348C cells. This fibroblast cell line was
used as a model for LDL receptor-expressing cells, since the
receptor expression is well defined in this cell line (Anderson et al,
1978) and not well defined in the retinoblastoma cells. Results
from experiments with retinoblastoma cells were similar (Figures 5
and 6). The results ofeach set ofexperiments are discussed below.
Determination of the optimal binding ratio
Different binding ratios ofCe6 molecules to the LDL carrier were
tested for cellular uptake efficiency. The results are presented in
Figure 2 for the fibroblast cell line. Ce6:LDL molar ratios ranged
from 10:1, 50:1, 100:1 to 1000:1. Ce6concentrations were deter-
mined by spectrophotometry, while the LDL quantification was
based on protein content. Optimal results were obtained at a
Ce6-LDL ratio of 50:1, which was used for further experiments.
Higher binding ratios apparently compromised the receptor
affinity. At all time points, uptake ofCe6 covalently bound to LDL
at a 50:1 ratio was 4-5 times higher than uptake offree Ce6.
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Figure 5 Uptake of Ce6 and Ce6-conjugate by the Y79 retinoblastoma cell
line. Subconfluent cell cultures of 1.5-2 x 106 cells were incubated with 0.5
gM free Ce6 or the same amount of LDL-conjugated Ce6 in 35-mm dishes for
2 h at 20C or 370C. As shown with fibroblasts, conjugates are taken up at a
significantly higher rate at all time points (P<0.05) and the uptake was
temperature dependent and saturable, consistent with a receptor-mediated
pathway. Error bars represent s.e.m. (P<0.05)
Evaluation of the effect of covalent binding
To evaluate effects caused by the formation of Ce6-LDL
complexes by non-covalent (lipophilic) interactions of the
compounds, Ce6 was mixed with LDL without covalent binding
and used for incubation. These data were compared with those
obtained from the treatment of the same cells with the covalent
conjugate at equivalent concentrations. Results shown for fibro-
blasts in Figure 3 demonstrated that the uptake ofmixed Ce6-LDL
(Ce6-mix) did not differ significantly from non-selective uptake of
free Ce6' In contrast, the uptake ofthe covalently bound compound
was significantly higher than free Ce6'
Effect of temperature on uptake
Data are presented for the fibroblasts in Figure 4. At 2°C, active
cellular mechanisms, such as phagocytosis and internalization, are
excluded. Unconjugated Ce6 is non-specifically attached to cell
membranes at low rates independent of the temperature and this
association plateaued out at both temperatures, possibly when
an extra- to intracellular equilibrium was achieved. Uptake of
Ce6-LDL conjugate was increased at 2°C, compared with Ce6,
probably because of increased initial binding owing to receptor
recognition. In addition, the uptake of receptor-bound Ce6-LDL
conjugate continued to increase with a decreasing slope at 37°C.
Uptake of unconjugated Ce6 and Ce6-LDL conjuate by
retinoblastoma cells
As with the fibroblast model, conjugation ofCe6 with LDL signifi-
cantly enhanced uptake ofthe photosensitizer in the retinoblastoma
cells (Figure 5). The uptake of Ce6-LDL by retinoblastoma cells
was temperature dependent and saturable (Figure 5). Compared
with Figure 4, the uptake of the Ce6 conjugate seems to be
enhanced for the retinoblastoma line. However, the absolute
amounts of uptake in this line proceed at a very low level, as the
cells are significantly smaller than fibroblasts. It is also possible
that LDL receptor expression and rate of metabolism vary consid-
erably between both cell types, since there is no available informa-
tion about LDL uptake for retinoblastoma cells. This might
also explain the differences in the saturable response at 370C.
However, the trend of an increased uptake of the conjugate vs free
Ce6 are identical.
Displacement ofCe6rLDL by free LDL
Addition of free LDL in fivefold excess following prebinding
of Ce6-LDL conjugate to retinoblastoma cells for 4 h led to a
decrease in Ce6 intracellular content. The data from these experi-
ments are shown in Figure 6; the arrow represents the 4-h point at
which free LDL is added. Presumably, the decrease in Ce6 intra-
cellular content following the addition of free LDL was due to
competitive saturation ofthe LDL receptor (Figure 6). In contrast,
cells incubated with Ce6-LDL conjugate only (without the addition
of LDL 4 h later) continued to show an increase in Ce6 content.
Saturation was indicated during the 1- and 2-h interval. However,
at longer incubation times, the proliferation rate and presentation
of newly formed LDL receptors probably exceed the saturation of
the early phase. Note also that at 37°C the amount ofmeasured Ce6
conjugate indicates internalized Ce6. Cells incorporate occupied
receptors and recycle free receptors back to their surface.
Phototoxicity of bound, complexed and free Ce6
The phototoxicity data on retinoblastoma cells treated with free,
complexed and conjugated Ce6 and light are presented in Figure 7.
Consistent with the increased uptake, photosensitization was most
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Figure 7 Phototoxicity to retinoblastoma cells of free Ce6, mixed and
covalently bound Ce6-LDL. A fluence of 10 J cm-2 with an irradiance of 50
mW cm-2 was delivered at 660 nm. Different binding or mixing ratios from
1:10 to 1:1000 of LDL:Ce6 were used. Cells were incubated with the complex
conjugate for 2 h. Dark controls received Ce6:LDL at a ratio of 50:1 without
light exposure. Cell survival was measured by determination of mitochondrial
activity using an MTT assay. The open bar shows Ce6 phototoxicity. Cells
were incubated with 4 nmol ofCe6 for 2 h. Error bars are s.e.m. (P<0.01)
effective with conjugated Ce6-LDL. Again, a ratio of 50:1 of
Ce6:LDL exhibited the highest phototoxicity. At this ratio, typi-
cally only 20% survival of cells was observed at a fluence of
10 J cm-2, while Ce6 in its free form showed no significant photo-
toxicity. The Ce6-LDL complex showed 80-90% cell survival.
None ofthecompounds showed dark toxicity.
DISCUSSION
Photodynamic strategies are attractive owing to their relatively
non-invasive nature and their potential for increased selectivity
compared with conventional treatment modalities. For the treat-
ment ofretinoblastomas only under conditions in which these two
aspects are fulfilled, PDT would be preferable to most established
methods, such as extermal beamradiotherapy, plaque radiotherapy,
cryotherapy and photocoagulation. Complications of radiation
therapy, however, are known to be serious: induction of second
cancers, retinopathy with visual loss, sunken globe, periorbital
bone deformities and central nervous system abnormalities are
well documented(Abramson et al, 1981; Sery, 1987; Shields et al,
1993). Therefore, alternative approaches, such as chemotherapy,
arecurrentlybeing discussed.
Targeted photochemotherapy should increase the ratio of
tumour toxicity to normal tissue toxicity by causing damage
primarily to target cells within a treatment site to which illumina-
tion is tightly confined. The most effective PS for PDT in vivo are
believed to derive their tumour localization by binding to lipopro-
teins followingsystemic administration (Jori et al, 1990). In addi-
tion, Jori and Reddi (1990) and others (Mosley et al, 1981; Allison
et al, 1994; Schmidt-Erfurth et al, 1994) have demonstrated that
many photosensitizers target tumour cells more efficiently when
precomplexed with LDL before administration in vivo. The moti-
vation for this study was to carry the encouraging results of these
previous investigations with PS-LDL complexes a step further and
to investigate whether covalent linking of PS to LDL would
provide an advantage over simple mixing of PS with LDL
(complex), both in terms of PS uptake and phototoxicity. In addi-
tion, complex formation leaves open the possibility of the PS
binding with other blood components that may not help tumour
targeting. In addition, the molecules that may be complexed to
LDL easily are limited by their hydrophilicity, since it is largely
the hydrophobic forces of a molecule that make the complex
formation possible (Jori, 1989).
Ce6 was selected as a sensitizing agent for this study over
haematoporphyrin derivative (HPD), which is the primary sensi-
tizer used clinically (Weishaupt et al, 1976; Bruce, 1987; Sery et al,
1987; Tse et al, 1989). Ce6 offers a high singlet oxygen quantum
yield and reduced skin phototoxicity (Moan et al, 1987). Also, it is
relatively less hydrophobic than HPD, so that the potential for
using LDL as a carrier for less hydrophobic molecules could also
be tested. Ce6 was covalently bound to LDL by peptide bond
formation catalysed by a carbodiimide reaction. Quantitative effec-
tiveness of the binding procedure and qualitative preservation of
the phototoxic potential of Ce6 had previously been shown by
coupling ofthe same compound to MAb and microspheres (Goff et
al, 1991, 1994; Bachor et al, 1991a, b, c). LDL seemed to be an
ideal carrier owing to the presence of significantly increased
numbers ofreceptors on cells with a high mitotic index (Gal et al,
1981; Vitols et al, 1985). Since there are no data available on the
distribution of LDL receptors on retinoblastoma cells, the conju-
gate was first tested infibroblastcultures, forwhichexpression and
regulation of the LDL receptor had previously been characterized
(Brown and Goldstein, 1975). The same group later demonstrated
targetedphototoxicity using pyrenecomplexed to LDL in the same
cell type (Anderson et al, 1978). Exactly how cells recognize and
endocytose LDL in its native or modified form is not completely
understood. Three mechanisms have been suggested. Firstly, the
apoB/E receptor, which is present on all cells, is the main mecha-
nism by which cells gain exogenous cholesterol and can be regu-
lated up or down to attain cholesterol homeostasis. There is some
evidence that malignant cells can up-regulate their expression of
the apoB/E receptor to satisfy their increased demand for choles-
terol as aresultoftheirgreaterrate ofsynthesis ofmembranelipids
(Rudling et al, 1990), and forming complexes or conjugates of
drugs with LDL has been proposed as a means of selectively
targeting tumours (Vitols, 1991). Secondly, the scavenger receptor
(SR) is present on cells ofthe monocyte-macrophage lineage. The
SR recognizes a wide range of ligands, including LDL, which has
had one-sixth (approximately 60) of its epsilon amino groups
(Haberland et al, 1984) modified either by acetylation or acylation
by lipid oxidation products from LDL oxidation (Parthasarathy,
1991). Thirdly, the apoB/E-mediated phagocytosis mechanism,
present on macrophages, recognizes LDL, which has been less
severely modified than described above (Tertov et al, 1989), and is
thought to depend upon an increase in aggregation of the LDL
particles (Khoo et al, 1988). Which, if any, of the above mecha-
nisms was responsible forthe increased efficacy ofPDT with LDL
conjugates in the present study is not clear. It may be that different
mechanism(s) will be dominant in different cell types. Differences
in the kinetics of Ce6-conjugates in fibroblasts compared with
retinoblastoma cells were evident at different temperatures in these
series (Figures 4 and 5). Such information may then be used for
designing appropriately modified LDL moieties.
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Any method ofconjugation to a receptor-targeting moiety needs
to preserve the receptor recognition capabilities of the targeting
molecule. Experiments in this investigation demonstrated that this
was the case for Ce6-LDL ratios of up to 50:1. In these experi-
ments, uptake of Ce6-LDL conjugates by fibroblasts and retino-
blastoma cells was about five times higher compared with free Ce6
Higher binding ratios than 50:1 gave lower uptake ofCe6, presum-
ably because they compromised the affinity of the receptor recog-
nition site, apoprotein B and E, where Ce6binding occurred on the
LDL protein.
In the present study, increased uptake directly translated into
enhanced phototoxicity in the same range as the uptake. Since
chemical binding is known to cause changes in the molecular
photophysics and, hence, in factors such as the singlet oxygen
quantum yield ofa sensitizer as well as its intracellular distribution
(Bachor et al, 1991c), the proportional increase or decrease in cell
kill is rarely predictable. Exposure to higher doses than 10 J cm-2
might have increased the photocytotoxicity further; however, the
borderline radiant exposure used appropriately demonstrated the
differential effects offree, complexed and bound Ce6. Although, as
shown in Figure 3, the photosensitizer content of cells is similar
for free and complexed Ce6, the complex appeared to be slightly
more phototoxic than the free Ce6. This may be due to Ce6-induced
photosensitization of LDL, resulting in lipid peroxidation prod-
ucts, which may be toxic to cells (Brown and Goldstein, 1975;
Maziere et al, 1990). Alternatively, the small difference in the
uptake or the intracellular site ofCe6 localization is responsible for
the increased phototoxicity with the Ce6-LDL complex.
The initial experiments with PDT and retinoblastoma cells were
performed by Sery et al (1979). Two cell lines, Y79 and WERI-
RB1, were photosensitized with HPD and white light, and the
resulting photodynamic effects were documented. Cell suspen-
sions were supplemented with HPD, incubated for different time
intervals and subsequently irradiated in the presence of HPD. The
highest phototoxicity was achieved when sensitization periods of
cell-dye contact were 6 h or longer. This extended interval demon-
strates the slow rate of non-specific accumulation of free photo-
sensitizer. When the HPD was washed out of the incubation
medium before irradiation, phototoxicity was significantly
reduced, similar to our observations with free Ce6. Apparently,
free HPD was not firmly bound to cells or internalized, but loosely
attached through non-specific interactions ordiffusion, in arapidly
reversible processes. When sensitizer bound to LDL was used in
our study, intensive washing did not reduce the phototoxicity of
Ce6-LDL, while free Ce6 was easily removed from the cells owing
to lack of receptor binding, consistent with Sery's experience.
Furthermore, HPD at very high concentrations of 16.7 gM was
required to achieve phototoxicity. Addition ofserum to the incuba-
tion medium induced an inhibitory effect on HPD phototoxicity,
which supports the important role of plasma factors for the
delivery (and removal) offree sensitizers.
Winther (1989) studied the effect of PF on a retinoblastoma-like
cell line, EXP-5, in vitro, after in vivo experiments with the same
cell line exhibited a tumour response of only 33%. Their results
indicated an extremely high sensitivity of retinoblastoma cells in
vitro to photodynamic treatment. A directly proportional relation
between light and PS dose and the level of phototoxicity was
found. In our study, an increased intracellular sensitizer concentra-
tion led to an enhanced phototoxicity, with an increased PS uptake
with the use of LDL carriers. Direct tumour cell targeting, there-
fore, may represent a realistic approach to increasing the efficient
PS concentration in tumour tissue, since the administration of
higher PS doses or an extension ofthe incubation interval has limi-
tations in vivo.
The contrast in high in vitro toxicity and low in vivo effects
observed by Winther (1989) is often explained by the influence of
PDT-induced hypoxia (Henderson and Fingar, 1987). For most PS
currently in experimental laboratory or clinical use, PDT induces
vascular occlusion and local ischaemia early during irradiation.
Lack ofoxygen, a critical mediatorofphototoxicity, then eliminates
photochemical effects in the tumour cells. Hence, to achieve
complete tumour cures, a delivery system that potentially leads to
specific accumulation within tumourcells is essential. Thetiming of
the irradiation (time point following PS administration) strongly
influences the site ofphototoxic damage (Zhou et al, 1988). When
the LDL-PS complexes orconjugates are used to deliver the PS for
in vivo PDT of tumours, the reaction of these species with endo-
thelial cells must be considered, since this is the barrier through
which the PS must pass if tumour cells are to be photosensitized.
Endothelial cells express the classical apoB/E receptor (high
affinity, low capacity) that leads to endocytosis via coated pits and
vesicles to endosomes and then to lysosomes where the apoB is
degraded and the cholesterol used in the cell. In addition, approxi-
mately 60% ofthe LDL taken upby the endothelium istranscytosed
by non-coated plasmalemmal vesicles or caveolae (low affinity,
high capacity) (Simionescu and Simionescu, 1991). Transcytosis is
not saturable (Rutledge et al, 1990); in conditions of hyperbetal-
ipoproteinaemia, large amounts of LDL can cross the endothelium
(Vasile et al, 1983). Receptors formildly oxidizedLDL,specifically
CD36 (Endenmann et al, 1993) have been found associated with
caveolin in endothelium (Lisanti etal, 1994), but thebinding mech-
anism for native LDL leading to transcytosis arepresently unclear.
Endothelial cells do not express the type I and II scavenger
receptors (Itakura et al, 1993) found on macrophages, which
recognize acetyl-LDL and highly oxidized LDL (Naito et al,
1992), but nevertheless their interaction with acetyl-LDL is well
known (Voyta, 1984). It seems likely that modified LDL is tran-
scytosed (and possibly further oxidized) by endothelial cells in
order for it to be endocytosed and degraded by macrophages and
smooth muscle cells. The question arises as to what extent LDL is
modified by formation ofcomplexes or covalentconjugates with a
PS? Although this issue was not investigated specifically in the
present study, it may be an important factor in producing the
enhanced phototoxicity with Ce6-LDL conjugates. It has been
suggested (Hamblin and Newman, 1994) that complex formation
between PS and LDL in vivo modifies the behaviour of the LDL
(perhaps with some oxidativeevent), so that the PS-LDLcomplex
behaves similarly to mildly oxidized LDL, being transcytosed by
the tumour microvasculature endothelium and accumulated in
tumour-associated macrophages. Allison et al (1994) found that
the photosensitizer BPD-MA was better delivered to tumours in
vivo associated with native LDL than with acetylated LDL. When
LDL-bound sensitizers are used, enhanced vascular effects are
seen at early exposure, and direct tumour cell kill is mostly found
after prolonged intervals, probably following the metabolic
pathway of LDL (Zhou et al, 1988). Direct targeting ofmalignant
cells with LDL (or other specific carriers) may decrease damage
to physiological tissue by a differential tumoricidal effect.
Additionally, side-effects could be reduced by administration of
significantly less sensitizer. Lower dose and potentially more
selective binding reduce cutaneous phototoxicity commonly seen
with HPD when lipoproteins are used as carriers (Jori et al, 1990).
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When we used LDL to deliver the PS, benzoporphyrin deriva-
tive mono-acid (BPD-MA), to treat an experimental melanoma in
vivo, vascular occlusion subsequent to endothelial damage was
a prominent feature following treatment soon after BPD-MA
injection (Schmidt-Erfurth et al, 1994, 1995a, b). In addition, data
(Schmidt-Erfurth et al, 1994) were also consistent with direct
tumour cell cytotoxicity.
Binding of LDL-sensitizer conjugates to neovascular endothe-
lium in addition to tumour cells has been attributed to receptor-
mediated binding of LDL by endothelial cells (Vlodavsky et al,
1978). This binding to endothelial cells may provide additional
targeting of tumour neovasculature, which would further enhance
phototoxicity (Roberts and Hasan, 1992). The ability of LDL to
pass microvascular barriers, particularly when the permeability is
increased, as seen in intraocular and other tumours (Roberts and
Hasan, 1993), provides a facilitated access of LDL-conjugates to
neoplastic tissue.
In summary, this initial study demonstrates an advantage to using
PS-LDL covalent conjugates. No attempt was made in these investi-
gations to optimize the PDT parameters, nor was there any attempt
to develop new techniques of conjugate synthesis or of exquisite
purification or characterization of the conjugates. These initial
encouraging results in the two cell lines tested warrant more rigorous
studies and also suggest considering PDT with PS-LDL conjugates
for intraocular and other malignancies. The use of carriers could
potentially provide a direct and more specific targeting with
increased efficiency and selectivity. Furthermore, it widens the
repertoire ofpotential sensitizers based on their phototoxic potential,
without the need of inherent selectivity or the ability to form
complexes with LDL on the part ofthe photosensitizer.
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